Characterization of RNF43 frameshift mutations that drive Wnt ligand‐ and R‐spondin‐dependent colon cancer
Open Access
- 4 March 2022
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 257 (1), 39-52
- https://doi.org/10.1002/path.5868
Abstract
Loss-of-function mutations in RNF43 induce activation of Wnt ligand-dependent Wnt/β-catenin signaling through stabilization of the Frizzled receptor, which is often found in microsatellite instability (MSI)-type colorectal cancer (CRC) that develops from sessile serrated adenomas. However, the mechanism underlying how RNF43 mutations promote tumorigenesis remains poorly understood. In this study, we established nine human CRC-derived organoids and found that three organoid lines carried RNF43 frameshift mutations associated with MSI-high and BRAFV600E mutations, suggesting that these CRCs developed through the serrated pathway. RNF43 frameshift mutant organoids required both Wnt ligands and R-spondin for proliferation, indicating that suppression of ZNRF3 and retained RNF43 function by R-spondin are required to achieve an indispensable level of Wnt activation for tumorigenesis. However, active β-catenin levels in RNF43 mutant organoids were lower than those in APC two-hit mutant CRC, suggesting a lower threshold for Wnt activation in CRC that developed through the serrated pathway. Interestingly, transplantation of RNF43 mutant organoids with intestinal myofibroblasts accelerated the β-catenin nuclear accumulation and proliferation of xenograft tumors, indicating a key role of stromal cells in the promotion of the malignant phenotype of RNF43 mutant CRC cells. Sequencing of subcloned organoid cell-expressed transcripts revealed that two organoid lines carried monoallelic RNF43 cis-mutations, with two RNF43 frameshift mutations introduced in the same allele and the wild-type RNF43 allele remaining, while the other organoid line carried two-hit biallelic RNF43 trans-mutations. These results suggest that heterozygous RNF43 frameshift mutations contribute to CRC development via the serrated pathway; however, a second-hit RNF43 mutation may be advantageous in tumorigenesis compared with a single-hit mutation through further activation of Wnt signaling. Finally, treatment with the PORCN inhibitor significantly suppressed RNF43 mutant cell-derived PDX tumor development. These results suggest a novel mechanism underlying RNF43 mutation-associated CRC development and the therapeutic potential of Wnt ligand inhibition against RNF43 mutant CRC.Funding Information
- Japan Agency for Medical Research and Development (19ck0106259h0003, 20ck0106541h0001)
- Japan Society for the Promotion of Science (18H04030, 19H03498)
- Takeda Science Foundation
This publication has 40 references indexed in Scilit:
- Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progressionNature Genetics, 2015
- RNF43 is frequently mutated in colorectal and endometrial cancersNature Genetics, 2014
- Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancerNature Genetics, 2014
- Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinomaProceedings of the National Academy of Sciences of the United States of America, 2013
- Molecular Dissection of Premalignant Colorectal Lesions Reveals Early Onset of the CpG Island Methylator PhenotypeThe American Journal of Pathology, 2012
- RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovaryThe Journal of Pathology, 2012
- Wnt5a Potentiates TGF-β Signaling to Promote Colonic Crypt Regeneration After Tissue InjuryScience, 2012
- Canonical Wnt signaling regulates Slug activity and links epithelial–mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repressionProceedings of the National Academy of Sciences of the United States of America, 2012
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancerNature Medicine, 2012